Topics

Articles

A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective. 

Finding the Ideal Set of Oncology Employer Benefits 

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

Identifying Trends Surrounding the Use of In-House Pharmacies for High-Cost Drugs

The annual report published by IQVIA examines movement surrounding drug launches and new clinical trials, during the post-pandemic era.

Investigating Trends in the Pharmaceutical Research & Development Space

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications. 

Almirall, Novo Nordisk Reach Licensing Agreement Surrounding IL-21 Blocking Monoclonal Antibodies

The financial commitment features construction of new warehouses in Pennsylvania and North Carolina. 

DHL Supply Chain Invests $200M Toward Expanding Its Life Sciences and Healthcare Services

The analysis notes that 60% of respondents were setting targets based on AI’s ability to either cut costs or boost productivity.

Survey: Pharma Execs Are Fully Embracing the Use of AI 

Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.

Roche Pulls Out of Agreement With Repare Therapeutics to Develop Novel Cancer Therapy

According to AbbVie, ImmunoGen's entire oncology portfolio could drive long-term revenue growth, giving the company a potential multi-billion dollar drug that is already on the market.

AbbVie Finalizes Deal to Acquire ImmunoGen With its Pipeline of Antibody Drug Conjugates 

Technavio analysis notes that an increase drug patent expirations could be a contributing factor. 

Forecast Predicts Generic Drug Market Will Grow Upwards of $175B Over the Next Three Years

The acquisition expands Merck’s portfolio in the veterinary pharma space. 

Business and Finance